Cargando…
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
Effective therapies are needed for the treatment of patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) with brain metastases. A trastuzumab radioisotope has been shown to localize in brain metastases of patients with HER2-positive MBC, and intracran...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376355/ https://www.ncbi.nlm.nih.gov/pubmed/33945296 http://dx.doi.org/10.1200/JCO.20.02822 |
_version_ | 1783740477252567040 |
---|---|
author | Lin, Nancy U. Pegram, Mark Sahebjam, Solmaz Ibrahim, Nuhad Fung, Anita Cheng, Anna Nicholas, Alan Kirschbrown, Whitney Kumthekar, Priya |
author_facet | Lin, Nancy U. Pegram, Mark Sahebjam, Solmaz Ibrahim, Nuhad Fung, Anita Cheng, Anna Nicholas, Alan Kirschbrown, Whitney Kumthekar, Priya |
author_sort | Lin, Nancy U. |
collection | PubMed |
description | Effective therapies are needed for the treatment of patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) with brain metastases. A trastuzumab radioisotope has been shown to localize in brain metastases of patients with HER2-positive MBC, and intracranial xenograft models have demonstrated a dose-dependent response to trastuzumab. METHODS: In the phase II PATRICIA study (ClinicalTrials.gov identifier: NCT02536339), patients with HER2-positive MBC with CNS metastases and CNS progression despite prior radiotherapy received pertuzumab plus high-dose trastuzumab (6 mg/kg weekly) until CNS or systemic disease progression or unacceptable toxicity. The primary end point was confirmed objective response rate (ORR) in the CNS per Response Assessment in Neuro-Oncology Brain Metastases criteria. Secondary end points included duration of response, clinical benefit rate (complete response plus partial response plus stable disease ≥ 4 or ≥ 6 months) in the CNS, and safety. RESULTS: Thirty-nine patients were treated for a median (range) of 4.5 (0.3-37.3) months at clinical cutoff. Thirty-seven patients discontinued treatment, most commonly because of CNS progression (n = 27); two remained on treatment. CNS ORR was 11% (95% CI, 3 to 25), with four partial responses (median duration of response, 4.6 months). Clinical benefit rate at 4 months and 6 months was 68% and 51%, respectively. Two patients permanently discontinued study treatment because of adverse events (left ventricular dysfunction [treatment-related] and seizure, both grade 3). No grade 5 adverse events were reported. No new safety signals emerged with either agent. CONCLUSION: Although the CNS ORR was modest, 68% of patients experienced clinical benefit, and two patients had ongoing stable intracranial and extracranial disease for > 2 years. High-dose trastuzumab for HER2-positive CNS metastases may warrant further study. |
format | Online Article Text |
id | pubmed-8376355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-83763552022-08-20 Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study Lin, Nancy U. Pegram, Mark Sahebjam, Solmaz Ibrahim, Nuhad Fung, Anita Cheng, Anna Nicholas, Alan Kirschbrown, Whitney Kumthekar, Priya J Clin Oncol ORIGINAL REPORTS Effective therapies are needed for the treatment of patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) with brain metastases. A trastuzumab radioisotope has been shown to localize in brain metastases of patients with HER2-positive MBC, and intracranial xenograft models have demonstrated a dose-dependent response to trastuzumab. METHODS: In the phase II PATRICIA study (ClinicalTrials.gov identifier: NCT02536339), patients with HER2-positive MBC with CNS metastases and CNS progression despite prior radiotherapy received pertuzumab plus high-dose trastuzumab (6 mg/kg weekly) until CNS or systemic disease progression or unacceptable toxicity. The primary end point was confirmed objective response rate (ORR) in the CNS per Response Assessment in Neuro-Oncology Brain Metastases criteria. Secondary end points included duration of response, clinical benefit rate (complete response plus partial response plus stable disease ≥ 4 or ≥ 6 months) in the CNS, and safety. RESULTS: Thirty-nine patients were treated for a median (range) of 4.5 (0.3-37.3) months at clinical cutoff. Thirty-seven patients discontinued treatment, most commonly because of CNS progression (n = 27); two remained on treatment. CNS ORR was 11% (95% CI, 3 to 25), with four partial responses (median duration of response, 4.6 months). Clinical benefit rate at 4 months and 6 months was 68% and 51%, respectively. Two patients permanently discontinued study treatment because of adverse events (left ventricular dysfunction [treatment-related] and seizure, both grade 3). No grade 5 adverse events were reported. No new safety signals emerged with either agent. CONCLUSION: Although the CNS ORR was modest, 68% of patients experienced clinical benefit, and two patients had ongoing stable intracranial and extracranial disease for > 2 years. High-dose trastuzumab for HER2-positive CNS metastases may warrant further study. Wolters Kluwer Health 2021-08-20 2021-05-04 /pmc/articles/PMC8376355/ /pubmed/33945296 http://dx.doi.org/10.1200/JCO.20.02822 Text en © 2021 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | ORIGINAL REPORTS Lin, Nancy U. Pegram, Mark Sahebjam, Solmaz Ibrahim, Nuhad Fung, Anita Cheng, Anna Nicholas, Alan Kirschbrown, Whitney Kumthekar, Priya Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study |
title | Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study |
title_full | Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study |
title_fullStr | Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study |
title_full_unstemmed | Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study |
title_short | Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study |
title_sort | pertuzumab plus high-dose trastuzumab in patients with progressive brain metastases and her2-positive metastatic breast cancer: primary analysis of a phase ii study |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376355/ https://www.ncbi.nlm.nih.gov/pubmed/33945296 http://dx.doi.org/10.1200/JCO.20.02822 |
work_keys_str_mv | AT linnancyu pertuzumabplushighdosetrastuzumabinpatientswithprogressivebrainmetastasesandher2positivemetastaticbreastcancerprimaryanalysisofaphaseiistudy AT pegrammark pertuzumabplushighdosetrastuzumabinpatientswithprogressivebrainmetastasesandher2positivemetastaticbreastcancerprimaryanalysisofaphaseiistudy AT sahebjamsolmaz pertuzumabplushighdosetrastuzumabinpatientswithprogressivebrainmetastasesandher2positivemetastaticbreastcancerprimaryanalysisofaphaseiistudy AT ibrahimnuhad pertuzumabplushighdosetrastuzumabinpatientswithprogressivebrainmetastasesandher2positivemetastaticbreastcancerprimaryanalysisofaphaseiistudy AT funganita pertuzumabplushighdosetrastuzumabinpatientswithprogressivebrainmetastasesandher2positivemetastaticbreastcancerprimaryanalysisofaphaseiistudy AT chenganna pertuzumabplushighdosetrastuzumabinpatientswithprogressivebrainmetastasesandher2positivemetastaticbreastcancerprimaryanalysisofaphaseiistudy AT nicholasalan pertuzumabplushighdosetrastuzumabinpatientswithprogressivebrainmetastasesandher2positivemetastaticbreastcancerprimaryanalysisofaphaseiistudy AT kirschbrownwhitney pertuzumabplushighdosetrastuzumabinpatientswithprogressivebrainmetastasesandher2positivemetastaticbreastcancerprimaryanalysisofaphaseiistudy AT kumthekarpriya pertuzumabplushighdosetrastuzumabinpatientswithprogressivebrainmetastasesandher2positivemetastaticbreastcancerprimaryanalysisofaphaseiistudy |